October 30th, 2011 by John Mandrola, M.D. in Research
No Comments »
You don’t want this…
When it comes to the risk of stroke in atrial fibrillation, it pays to be a boy. Sorry, ladies.
An important question came up on my recent post on AF and stroke.
Why does being female give you an automatic point on CHADS2-VASc? I keep seeing it, but I don’t see why that is.
It doesn’t seem intuitive that female AF patients should have more strokes. Why? AF should equal AF.
But it does matter. When it comes to AF and stroke, women are very different.
Here are three references that support the fact that female gender increases the risk of stroke in AF.
–First: Read more »
*This blog post was originally published at Dr John M*
August 4th, 2011 by AndrewSchorr in Opinion, Research
No Comments »
There are big companies like Quintiles that run clinical trials around the world. There are local clinics that specialize in clinical trials and make a lot of money at it. There are, of course, pharmaceutical companies and device manufacturers who depend upon the results to gain marketing approval for new products. People in all those groups know a lot about trials.
But the perspective that counts is the view from you and me – patients. Most of us do not enroll in clinical trials. We don’t want to get too up close and personal with anything “experimental.” And often our doctors never tell us about available trials anyway since it can be a lot of paperwork for them. Given that most people don’t enroll in trials and new science is delayed because of it and also because most people in trials are not journalists, I thought I’d put hunt and peck to the computer keyboard and speak out about trials. I am especially motivated because I have participated twice. The first one, a leukemia trial in 2000, I believe, saved my life. And I enrolled in a second one, studying a new drug for clots in the legs (deep vein thrombosis or DVT) just a week and a half ago.
I enrolled in the DVT trial because 1) the first one worked for me and 2) I crow all the time about how patients should always consider being in a trial as a treatment option. I had to put up or shut up. So I signed on the dotted line.
This particular trial, Read more »
*This blog post was originally published at Andrew's Blog*
June 27th, 2010 by John Mandrola, M.D. in Better Health Network, Opinion, Research, True Stories
No Comments »
In cancer treatment, detection of a tumor in an early stage markedly increases the chance of favorable outcomes.
Can the much-aligned blood thinner, warfarin, occasionally help in early detection of cancer?
Few pharmacologic agents receive more bad press than warfarin. Stories, which are too numerous to count, like “Did warfarin kill my father,” can be widely found on Internet forums, search engines, and are often quoted by reluctant patients — whose numerator of bad warfarin experiences is one.
It is true that warfarin has a narrow therapeutic window — a small difference between an effective dose and dangerous dose. Read more »
*This blog post was originally published at Dr John M*
